11,041 results match your criteria: "the University of Texas M.D. Anderson Cancer Center[Affiliation]"

Significant progress in determining the molecular origins and resistance mechanisms of mantle cell lymphoma (MCL) has improved our understanding of the disease's clinical diversity. These factors greatly impact prognosis in MCL patients. Given the dynamic alterations in MCL clones and disease evolution, it is crucial to recognize high-risk prognostic factors at diagnosis and relapse.

View Article and Find Full Text PDF

The joint College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee works to ensure the competency and proficiency of clinical cytogenetic testing laboratories through proficiency testing (PT) programs for various clinical tests offered by such laboratories, including the evaluation of cytogenetic abnormalities in solid tumors. Review and analyze 25 years (1999-2023) of solid tumor chromosome analysis PT results, utilizing G-banded karyograms. A retrospective review of results from 1999 to 2023 was performed, identifying the challenges addressing solid tumors.

View Article and Find Full Text PDF

Background: Identifying risk factors for local recurrence (LR) is pivotal in optimizing rectal cancer treatment. Total mesorectal excision (TME) and lateral lymph node dissection (LLND) are the standard treatment for advanced low rectal cancer in Japan. However, large-scale studies to evaluate risk factors for LR are limited.

View Article and Find Full Text PDF

Squamous cell carcinomas (SCC) are often preceded by potentially malignant precursor lesions, most of which remain benign. The terminal exhaustion phenotypes of effector T-cells and the accumulation of myeloid-derived suppressor cells (MDSC) have been thoroughly characterized in established SCC. However, it is unclear what precancerous lesions harbor a bona fide high risk for malignant transformation and how precancerous epithelial dysplasia drives the immune system to the point of no return.

View Article and Find Full Text PDF

PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)-mediated antitumoral immune responses. We hypothesized that the PARP inhibitor olaparib would also potentiate radiation-induced T1IFN to promote antitumor immune responses and sensitization of otherwise resistant PDAC to immunotherapy.

View Article and Find Full Text PDF

Development of a RIPK1 degrader to enhance antitumor immunity.

Nat Commun

December 2024

The Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.

The scaffolding function of receptor interacting protein kinase 1 (RIPK1) confers intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs) and emerges as a promising target for improving cancer immunotherapies. To address the challenge posed by a poorly defined binding pocket within the intermediate domain of RIPK1, here we harness proteolysis targeting chimera (PROTAC) technology to develop a RIPK1 degrader, LD4172. LD4172 exhibits potent and selective RIPK1 degradation both in vitro and in vivo.

View Article and Find Full Text PDF

In vitro hydrolysis of areca nut xenobiotics in human liver.

Drug Metab Pharmacokinet

November 2024

Department of Diagnostic & Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address:

Areca nut (AN) is a substance of abuse consumed by millions worldwide, in spite of established oral and systemic toxicities associated with its use. Previous research demonstrates methyl ester alkaloids in the AN, such as arecoline and guvacoline, exhibit mood-altering and toxicological effects. Nonetheless, their metabolism has not been fully elucidated in humans.

View Article and Find Full Text PDF

Background And Purpose: With the availability of commercial electronic portal imaging detector-based in vivo dosimetry (EPID-based IVD) solutions, many radiotherapy departments are adopting this technology. However, comprehensive commissioning guidance is lacking. This study aims to provide a protocol for testing the accuracy and sensitivity of EPID-based IVD systems.

View Article and Find Full Text PDF

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

N Engl J Med

December 2024

From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).

Article Synopsis
View Article and Find Full Text PDF

Effectively targeting intracellular tumor-associated proteins presents a formidable challenge in oncology, as they are traditionally considered inaccessible to conventional antibody-based therapies and CAR-T cell therapies. However, recent advancements in antibody engineering have revolutionized this field, offering promising new strategies to combat cancer. This review focuses on the innovative use of T-cell receptor mimic (TCRm) antibodies within the therapeutic frameworks of T-cell engagers (TCE) and antibody-drug conjugates (ADCs).

View Article and Find Full Text PDF

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.

N Engl J Med

October 2024

From Baylor College of Medicine (S.P.L.) and the University of Texas M.D. Anderson Cancer Center (A.M.K.), Houston, the University of Texas Health San Antonio (R.S.S.) and CHRISTUS Santa Rosa Medical Center Hospital (I.M.T.), San Antonio, and the University of Texas Southwestern Medical Center, Dallas (A.I.S.) - all in Texas; Stanford University, Stanford (E.S.), Norris Comprehensive Cancer Center, University of Southern California, Los Angeles (S.D., A.S.), and City of Hope Medical Center, Duarte (S.K.P.) - all in California; SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center - both in Seattle (C.T., M.P.); the Ohio State University, Columbus (K.S.P.); the University of Chicago, Chicago (N.D.S.); McGill University Health Center, Montreal (W.K.); the Bladder Cancer Advocacy Network, SWOG Advocates, Pittsford, NY (R.B.); Oregon Health and Science University, Portland (T.M.K.); the University of Michigan, Ann Arbor (A.A.); the University of Colorado, Aurora (F.G.L.R.); Brigham and Women's Hospital, Boston (A.S.K.); Fox Chase Cancer Center, Philadelphia (D.J.C.); and Oschsner Medical Center, Jefferson, LA (D.J.C.).

Background: Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder cancer undergoing radical cystectomy is unclear.

Methods: We randomly assigned, in a 1:1 ratio, patients with localized muscle-invasive bladder cancer of clinical stage T2 (confined to muscle) to T4a (invading adjacent organs) with two or fewer positive nodes (N0, N1, or N2) to undergo bilateral standard lymphadenectomy (dissection of lymph nodes on both sides of the pelvis) or extended lymphadenectomy involving removal of common iliac, presciatic, and presacral nodes. Randomization was performed during surgery and stratified according to the receipt and type of neoadjuvant chemotherapy, tumor stage (T2 vs.

View Article and Find Full Text PDF

Data-Driven Cutoff Selection for the Patient Health Questionnaire-9 Depression Screening Tool.

JAMA Netw Open

November 2024

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.

Article Synopsis
  • The study investigates how using small datasets to select an optimal cutoff score for the Patient Health Questionnaire-9 (PHQ-9) can lead to inaccurate results.
  • Researchers evaluated whether data-driven methods for cutoff selection resulted in scores that were significantly different from the true population optimal score and if these methods produced biased accuracy estimates.
  • Findings showed that many small studies frequently failed to identify the correct optimal cutoff score, particularly in smaller samples, leading to an overestimation of test sensitivity.
View Article and Find Full Text PDF

Cyclin D1-negative mantle cell lymphoma (MCL) is regarded as a B-cell neoplasm that has morphologic and immunophenotypic findings indistinguishable from typical MCL. These neoplasms lack cyclin D1 overexpression by immunohistochemistry and t(11;14)(q13;q32)/IGH::CCND1. Since cyclin D1-negative MCL was first recognized by gene expression profiling in 2003, there has been diagnostic confusion regarding this entity, mostly attributable to a lack of diagnostic tools to recognize these neoplasms in most clinical laboratories.

View Article and Find Full Text PDF
Article Synopsis
  • * Research is examining ways to lessen treatment intensity (de-escalation), particularly to reduce side effects from radiotherapy while maintaining effective cancer management for HPV-positive patients.
  • * Although some Phase II trials show promise for de-escalation strategies, current Phase III trials have not yet shown improved outcomes, indicating a need for more research and better risk assessment before these strategies can be routinely used outside clinical trials.
View Article and Find Full Text PDF

Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2-years after biologic assignment to a Donor or No Donor (SOC) Arm based on the availability of an HLA-matched sibling or unrelated donor (BMTCTN 1503; NCT02766465). A donor search was commenced after eligibility confirmation.

View Article and Find Full Text PDF
Article Synopsis
  • - The study reviews current immunotherapy approaches for small bowel neuroendocrine tumors (SBNET) and explores future avenues for better treatment responses
  • - Key treatments like somatostatin analogs and mTOR inhibitors are essential, while new applications of peptide receptor radionuclide therapy (PRRT) show promise, though existing immunotherapies have had limited success
  • - Increased incidence of SBNET highlights the need for more effective therapies, and further research into the immune microenvironment may uncover new targets for improved patient outcomes
View Article and Find Full Text PDF

Therapeutic approaches to modulate the immune microenvironment in gliomas.

NPJ Precis Oncol

October 2024

Center for Neuro-Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

Article Synopsis
  • Immunomodulatory therapies, especially immune checkpoint inhibitors, have improved cancer treatment outcomes over the past decade, but gliomas show limited response to these therapies due to their complex immune microenvironment.
  • * The glioma immune microenvironment includes various cells such as macrophages, myeloid-derived suppressor cells, neutrophils, microglia, and lymphocytes, which contribute to the ineffective response to existing treatments.
  • * Recent efforts focus on understanding this unique environment and developing new therapies, including oncolytic viruses, vaccines, and cell-based therapies like CAR-T and CAR-NK cells, which are currently in clinical trials.
View Article and Find Full Text PDF

IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.

Cell

December 2024

Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:

Article Synopsis
  • Chemotherapy combined with immune checkpoint inhibitors (ICIs) is used to boost immunotherapy effectiveness, but certain tumors, especially triple-negative breast cancer (TNBC), often remain unresponsive.
  • The study identifies IRE1α, an ER stress sensor, as a key factor that limits the immune-boosting effects of taxane chemotherapy in these tumors by silencing double-stranded RNA (dsRNA) and preventing a type of inflammatory cell death called pyroptosis.
  • Inhibiting IRE1α allows taxane to produce more dsRNA, which activates immune responses, transforming PD-L1-negative TNBC tumors into ones that are sensitive to immunotherapy.
View Article and Find Full Text PDF

Impact of Six Months of Three Different Modalities of Exercise on Stress in Post-Treatment Breast Cancer Survivors.

Cancers (Basel)

October 2024

Department of Population Health Sciences, Institute for Health Promotion Research, University of Texas Health-San Antonio, 7411 John Smith Drive, Suite 1000, San Antonio, TX 78229, USA.

Background/objectives: Extensive evidence suggests that exercise is physically and mentally beneficial for cancer survivors. This study reports on changes in self-reported stress, physiological biomarkers for stress (salivary cortisol), and HR-QOL constructs for fifty breast cancer survivors participating in one of three different exercise programs over 6 months.

Methods: Fifty post-treatment breast cancer survivors were randomized to either therapeutic yoga-based exercise (YE), comprehensive exercise (CE) (aerobic, resistance, flexibility), or choosing (C) their own exercise activities.

View Article and Find Full Text PDF

Introduction: In this study, we evaluate the association between sociodemographics and disease presentation, treatment, and survival for children, adolescents, and young adults with Ewing sarcoma.

Methods: Case-level data were downloaded from The Surveillance, Epidemiology, and End Results database. Cases included patients ages 0-24 who were diagnosed with Ewing sarcoma between 2004 and 2020.

View Article and Find Full Text PDF

Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling.

Gastroenterology

October 2024

Department of Surgery, Case Western Reserve University, Cleveland, Ohio; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio; Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Electronic address:

Article Synopsis
  • Therapy failure in metastatic colorectal cancer (mCRC), particularly in the liver, is a significant issue; new strategies are needed as existing HER3-targeting therapies have underperformed in clinical settings.
  • Research focused on how liver-derived factors, specifically leucine-rich alpha-2-glycoprotein 1 (LRG1), trigger a non-canonical HER3 activation pathway, facilitating CRC growth independent of traditional HER3 signaling.
  • Targeting the LRG1-HER3 interaction may offer novel treatment options for mCRC, showing promise for improving patient outcomes and tackling liver metastases.
View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic affected many countries and led to strict health rules that caused economic problems too.
  • Researchers studied how international flights influenced the spread of COVID-19 using a special computer model called Dynamic Weighted GraphSAGE (DWSAGE).
  • Their findings showed that areas like Western Europe, the Middle East, and North America had a big impact on the pandemic due to lots of air traffic, and they suggested ways to reduce flights to help control it.
View Article and Find Full Text PDF

Introduction: Cancer survivors experienced poorer health-related quality of life (HRQoL) and greater psychological distress during the COVID-19 pandemic than those without cancer. However, the underlying mechanisms that may explain how negative experiences during the pandemic are associated with distress and HRQoL remain unknown. We examined whether psychosocial risk factors (i.

View Article and Find Full Text PDF

Low-cost optical imaging technologies have the potential to reduce inequalities in healthcare by improving the detection of pre-cancer or early cancer and enabling more effective and less invasive treatment. In this Review, we summarise technologies for in vivo widefield, multi-spectral, endoscopic, and high-resolution optical imaging that could offer affordable approaches to improve cancer screening and early detection at the point-of-care. Additionally, we discuss approaches to slide-free microscopy, including confocal imaging, lightsheet microscopy, and phase modulation techniques that can reduce the infrastructure and expertise needed for definitive cancer diagnosis.

View Article and Find Full Text PDF